相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and Safety of Pharmacologic Interventions in Patients Experiencing a Gout Flare: A Systematic Review and Network Meta-Analysis
Linan Zeng et al.
ARTHRITIS CARE & RESEARCH (2021)
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)
John K. Botson et al.
JOURNAL OF RHEUMATOLOGY (2021)
Reassessing the Cardiovascular Safety of Febuxostat: Implications of the Febuxostat versus Allopurinol Streamlined Trial
Hyon K. Choi et al.
ARTHRITIS & RHEUMATOLOGY (2021)
A Randomized, Phase II Study Evaluating the Efficacy and Safety of Anakinra in the Treatment of Gout Flares
Kenneth G. Saag et al.
ARTHRITIS & RHEUMATOLOGY (2021)
The effect of immunomodulators on the efficacy and tolerability of pegloticase: a systematic review
Robert T. Keenan et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)
Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
Puja P. Khanna et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities
Lisa K. Stamp et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Cardiovascular Safety of Febuxostat and Allopurinol in Hyperuricemic Patients With or Without Gout: A Network Meta-Analysis
Shengzhao Zhang et al.
FRONTIERS IN MEDICINE (2021)
Inequities in people with gout: a focus on Maori (Indigenous People) of Aotearoa New Zealand
Leanne Te Karu et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2021)
Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review
Hamish Farquhar et al.
RHEUMATOLOGY ADVANCES IN PRACTICE (2021)
Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review
Huai Leng Pisaniello et al.
ARTHRITIS RESEARCH & THERAPY (2021)
12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
Till Uhlig et al.
RMD OPEN (2021)
2020 American College of Rheumatology Guideline for the Management of Gout
John D. FitzGerald et al.
ARTHRITIS CARE & RESEARCH (2020)
Comparative efficacy of traditional non-selective NSAIDs and selective cyclo-oxygenase-2 inhibitors in patients with acute gout: a systematic review and meta-analysis
Mengtao Li et al.
BMJ OPEN (2020)
The Molecular Mechanisms That Underlie the Immune Biology of Anti-drug Antibody Formation Following Treatment With Monoclonal Antibodies
Anna Vaisman-Mentesh et al.
FRONTIERS IN IMMUNOLOGY (2020)
Pathophysiology of Gout
Ravi K. Narang et al.
SEMINARS IN NEPHROLOGY (2020)
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
Isla S. Mackenzie et al.
LANCET (2020)
LEFLUNOMIDE CO-THERAPY WITH PEGLOTICASE IN UNCONTROLLED GOUT
K. Masri et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial
Viola Kluck et al.
LANCET RHEUMATOLOGY (2020)
Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial
Ted R. Mikuls et al.
AMERICAN JOURNAL OF MEDICINE (2019)
Anakinra for the treatment of acute gout flares: a randomized, double-blind, placebo-controlled, active-comparator, non-inferiority trial
Carly A. Janssen et al.
RHEUMATOLOGY (2019)
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout
William B. White et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
OLT1177, a ß-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation
Carlo Marchetti et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
Serum urate as surrogate endpoint for flares in people with gout: A systematic review and meta-regression analysis
Lisa Stamp et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
A Case Report of Immunosuppressant Medication-Associated Polyarticular Tophaceous Gout Successfully Treated Using the Polyethylene Glycol-Conjugated Uricase Enzyme Pegloticase
B. Freyne
TRANSPLANTATION PROCEEDINGS (2018)
Development of the American College of Rheumatology Electronic Clinical Quality Measures for Gout
John D. FitzGerald et al.
ARTHRITIS CARE & RESEARCH (2018)
Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert
Hyon Choi et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial
Michael Doherty et al.
LANCET (2018)
NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis
Carlo Marchetti et al.
ARTHRITIS RESEARCH & THERAPY (2018)
Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: results from FORTUNE-1, a prospective, multicentre randomised study
Hisashi Yamanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians
Amir Qaseem et al.
ANNALS OF INTERNAL MEDICINE (2017)
2016 updated EULAR evidence-based recommendations for the management of gout
P. Richette et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The British Society for Rheumatology Guideline for the Management of Gout
Michelle Hui et al.
RHEUMATOLOGY (2017)
Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout
Adey A. Berhanu et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
The effect of kidney function on the urate lowering effect and safety of increasing allopurinol above doses based on creatinine clearance: a post hoc analysis of a randomized controlled trial
Lisa K. Stamp et al.
ARTHRITIS RESEARCH & THERAPY (2017)
Allopurinol dose escalation to achieve serum urate below 6 mg/dL: an open-label extension study
Lisa K. Stamp et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
A randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout
Lisa K. Stamp et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Allopurinol hypersensitivity: investigating the cause and minimizing the risk
Lisa K. Stamp et al.
NATURE REVIEWS RHEUMATOLOGY (2016)
Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH)
Jason J. Lee et al.
CLINICAL MEDICINE INSIGHTS-ARTHRITIS AND MUSCULOSKELETAL DISORDERS (2016)
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
Michael S. Hershfield et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
Peter E. Lipsky et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions
Naomi Schlesinger et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Patient and provider barriers to effective management of gout in general practice: a qualitative study
Karen Spencer et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2012)
Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout - Results of a phase II randomized study
John S. Sundy et al.
ARTHRITIS AND RHEUMATISM (2008)
Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy
Michael A. Becker et al.
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2008)
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
MA Becker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy
A Shoji et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2004)
Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis
F Perez-Ruiz et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2003)
分享论文
